z-logo
Premium
Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus
Author(s) -
Sinha V. P.,
Howey D. C.,
Choi S. L.,
Mace K. F.,
Heise T.
Publication year - 2014
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12222
Subject(s) - pharmacokinetics , insulin , medicine , endocrinology , basal (medicine) , type 2 diabetes mellitus , diabetes mellitus , hypoglycemia , area under the curve , type 1 diabetes , type 2 diabetes
Aims To assess the pharmacokinetics ( PK ) and glucodynamics ( GD ) of LY2605541 in patients with type 2 diabetes mellitus. Methods This parallel‐group, open‐label, dose‐escalation study examined the PK and GD of basal insulin LY2605541 after single and multiple‐dose administration. Fixed doses of LY2605541 (0.33–1.00 U/kg) were given once‐daily ( QD ) for 14 days to insulin‐treated patients with type 2 diabetes. A 24‐h euglycaemic glucose clamp was conducted on days 1 and 14. Results PK steady state was achieved within 7–10 days and the peak‐to‐trough fluctuation was <2, translating to a nearly ‘peakless’ glucose infusion rate at steady state and with a duration of action of at least 24 h. Across dose levels t 1/2 ranged from 44.7 to 75.5 h (˜2–3 days). As steady state was achieved, there were dose‐dependent reductions in the prandial insulin dose and in fasting blood glucose, which decreased to 60–100 mg/dl across dose levels. Within‐patient variability was <14 and <26% for the area under the concentration versus time curve ( AUC ) of the 8‐point blood glucose profile and fasting blood glucose, respectively. The nocturnal glucose control between 03:00 and 09:00 hours was relatively unchanged. Mild hypoglycaemia was the most common adverse event. Conclusions In this Phase I study of fixed LY2605541 doses without titration, LY2605541 was well‐tolerated and demonstrated a flat PK and GD profile accompanied by glucose normalization, prandial insulin dose reduction and no severe hypoglycaemia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here